InspireMD

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Tel Aviv, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

InspireMD reports strong Q1 performance, eyes future growth opportunities

InspireMD's Q1 2024 showcased revenue growth and promising trial results, but challenges in gross profit and rising expenses. Strategic agreements and upcoming product approvals present opportunities for future growth and innovation.

InspireMD reports revenue growth, faces cost challenges, eyes U.S. launch

InspireMD's Q2 2024 performance reflects revenue growth but challenges in managing costs and achieving profitability.
The company's strengths lie in groundbreaking clinical outcomes, successful financings, and preparations for a U.S. commercial launch.
While facing cost and financial challenges, InspireMD has opportunities to drive market expansion, innovation, and capitalize on its strong cash position.
Balancing growth initiatives with cost control will be key for InspireMD's sustainable financial success and market competitiveness.

InspireMD reports 16% revenue growth in Q3 2024 earnings call

InspireMD's Q3 performance reflects revenue growth but challenges in profitability due to cost dynamics.
The company's strategic strengths lie in international sales, product innovation, and U.S. market focus.
Opportunities include FDA approvals, market expansion, and strong financial position for growth initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

InspireMD, Inc. is medical device company, which engages in the development and commercialization of its proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. Its products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction and saphenous vein graft coronary interventions. The company was founded in 2005 and is headquartered in Miami, FL.

TEL AVIV, Israel, April 14, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR, NSPR.WS, NSPR.WSB), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of Carotid Artery Disease (CAD), today announced a 1-for-15 reverse split of its common stock, effective as of April 26, 2021. Beginning on April 27, 2021, the Company's common stock will trade on the NYSE American on a split adjusted basis.

InspireMD Announces 1-for-15 Reverse Stock Split

TEL AVIV, Israel, March 22, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, today issues a message to stockholders from InspireMD CEO, Marvin Slosman regarding the Company's Special Meeting of Stockholders.

InspireMD CEO Marvin Slosman Issues Letter to Fellow Stockholders Urging Support of the Company's Plans to List its Common Stock on Nasdaq at the Upcoming Special Meeting of Stockholders

InspireMD, Inc.'s (NSPR) CEO Marvin Slosman on Q4 2020 Results - Earnings Call Transcript

Management to host investor conference call today, March 9, at 8:30am ET Management to host investor conference call today, March 9, at 8:30am ET

InspireMD Announces Fourth Quarter and Year-End 2020 Financial Results

Earnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET Earnings conference call to be held Tuesday, March 9, 2021 at 8:30 a.m. ET

InspireMD to Report Fourth Quarter and Year-End 2020 Financial Results on Tuesday, March 9, 2021 and Provide Corporate Update

TEL AVIV, Israel, Feb. 24, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today that it has engaged Hart Clinical Consultants (HCC), a leading Contract Research Organization (CRO) to conduct the clinical trial for its CGuard Carotid Stent System in the United States.

InspireMD Engages Hart Clinical Consultants to Conduct Clinical Trial for CGuard Carotid Stent System in the United States

TEL AVIV, Israel, Feb. 09, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease, announced today the appointment of Chris Metzger, M.D., system chair of clinical research at Ballad Health System in Eastern Tennessee as the principal investigator for its planned FDA registration trial for CGuard EPS.

InspireMD Appoints Leading Interventional Cardiologist Chris Metzger, M.D. as Principal Investigator for CGuard Registration Trial in the United States

TEL AVIV, Israel, Feb. 08, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East and Asia, today announced the closing of an upsized underwritten public offering of units for gross proceeds of approximately $20.7 million, which includes the full exercise of the underwriter's over-allotment option to purchase additional shares and warrants, prior to deducting underwriting discounts and commissions and offering expenses payable by InspireMD.

InspireMD Announces Closing of an Upsized $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option

The stock price of InspireMD Inc (NYSEAMERICAN: NSPR) is trading at over 10% pre-market as of 7:33 AM ET. This is why it happened.

NSPR Stock Price Increases Over 10% Pre-Market: Why It Happened

TEL AVIV, Israel, Feb. 04, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. ("InspireMD") (NYSE:NSPR), a medical device company focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East and Asia, today announced the pricing of an upsized underwritten public offering of securities for gross proceeds of $18 million (or $20.7 million if the underwriters exercise their option to purchase additional securities) prior to deducting underwriting discounts and estimated offering expenses payable by InspireMD.

InspireMD Announces Pricing of Upsized $18 Million Underwritten Public Offering

New Chinese Distributor Will Also Invest in At-The-Market Private Placement New Chinese Distributor Will Also Invest in At-The-Market Private Placement

InspireMD Secures Partner for Intended Registration and Distribution of CGuard EPS in Mainland China

TEL AVIV, Israel, Jan. 26, 2021 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of the stroke caused by carotid artery disease, announced today multiple presentations regarding CGuard EPS, including a live demonstration, during the Leipzig Interventional Congress being held virtually from January 25-29, 2021.

InspireMD's CGuard™ Featured in Multiple Presentations, Including a Live Case Demonstration During the Leipzig Interventional Congress January 25-29, 2021

InspireMD, Inc. (NSPR) CEO Marvin Slosman on Q3 2020 Results - Earnings Call Transcript

TEL AVIV, Israel, Nov. 03, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces the appointment of Andrea Tommasoli as senior vice president of global sales and marketing.

UPDATE - InspireMD, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing and Reports Inducement Grants Under NYSE American Company Guide §711(a)

InspireMD, Inc. Appoints Andrea Tommasoli Senior Vice President of Global Sales and Marketing and Reports Inducement Grants Under NYSE American Company Guide §711(a)

Earnings conference call to be held Monday, November 9, 2020 at 8:30 a.m. ET Earnings conference call to be held Monday, November 9, 2020 at 8:30 a.m. ET

InspireMD to Report Third Quarter 2020 Financial Results on Monday, November 9, 2020 and Provide Corporate Update

TEL AVIV, Israel, Oct. 13, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced the addition of Gary Roubin, M.D., Ph.D., to InspireMD’s Board of Directors.

InspireMD Announces Renowned Interventional Cardiologist Gary S. Roubin, M.D.

TEL AVIV, Israel, Oct. 06, 2020 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR) (“Company”), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announced the appointment of Patrick Jamnik as vice president, business development and strategic initiatives. In this newly created position, Mr. Jamnik will oversee the Company’s business development activities and play a key role in advancing its short and long-term strategic goals, with much of his focus being the U.S. market.

InspireMD, Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives and Reports Inducement Grants Under NYSE American Company Guide §711(a)

Advancing the CARENET-III study of CGuard System for Stroke Prevention in the United States Advancing the CARENET-III study of CGuard System for Stroke Prevention in the United States

InspireMD Announces Christina Brennan, M.D., MBA to Serve in Advisory Role for Pivotal Study of CGuard Carotid Stent System

IDE Approval to Pave the Way for Pivotal Study of CGuard System for Carotid Artery Disease and Stroke Prevention in the United States IDE Approval to Pave the Way for Pivotal Study of CGuard System for Carotid Artery Disease and Stroke Prevention in the United States

InspireMD Announces Approval of Investigational Device Exemption (IDE) for Pivotal Study of CGuard Carotid Stent System

TEL AVIV, Israel, Sept.  03, 2020  (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), the developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by carotid artery disease (CAD), today announces the award for Best ESC Congress Poster for the presentation of updated data from the large, long-term PARADIGM-EXTEND study of the CGuard™ Embolic Prevention System (EPS), as part of the European Society of Cardiology 2020 Carotid Update e-presentation at the European Society of Cardiology (ESC) Congress 2020. PARADIGM/EXTEND is an investigator-driven on-going study performed with CGuard Carotid stent for primary and secondary stroke prevention in a large, consecutive all-comers population, with 5 years (60 months) follow-up.

InspireMD Announces the European Society of Cardiology 2020 “Best Poster Award” for Updated Data from the PARADIGM-EXTEND Study

TEL AVIV, Israel, Aug.  25, 2020  (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that Marvin Slosman, President and Chief Executive Officer, will give a virtual corporate presentation at the LD Micro 500 taking place online on Thursday, September 3, 2020 at 4:20 PM EST followed by a live Q&A session with registered investors and other conference attendees.

InspireMD to Present at the LD Micro 500 Virtual Conference on September 3, 2020

TEL AVIV, Israel, Aug.  10, 2020  (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment of carotid artery disease, today announced that as of August 7, 2020, the Company has regained compliance with the NYSE American’s continued listing standards.

InspireMD Regains Compliance with NYSE AMERICAN Listing Standards

InspireMD's (NSPR) CEO Marvin Slosman on Q2 2020 Results - Earnings Call Transcript

 In the second quarter the Company was granted approval to market its   CGuard™ MicroNet stent in Brazil and completed an $11.5 million capital raise; reported outstanding results in studies treating patients with the CGuard™ MicroNET stent

News for InspireMD Stock (NSPR)